Literature DB >> 324502

Comparison of lidoflazine and quindine in prophylactic treatment of arrhythmias.

B M Kennelly.   

Abstract

The efficacy of quinidine versus lidoflazine therapy was compared in the maintenance of sinus rhythm after electrical cardioversion for atrial flutter or fibrillation in a group of 35 patients. Both quinidine and lidoflazine were relatively ineffective in maintaining sinus rhythm after cardioversion. Lidoflazine was also used to prevent supraventricular and ventricular tachycardias in a miscellaneous group of patients; one of these with paroxysmal supraventricular tachycardia developed runs of venttricular tachycardia soon after starting lidoflazine. The trial was stopped after 4 patients died while receiving lidoflazine, on the suspicion that their deaths may have been related to drug-induced arrhythmias. The arrhythmogenic potential of lidoflazine when used in patients with supraventricular arrhythmias constrasts with reports of its apparent safety in large numbers of patients with angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324502      PMCID: PMC483272          DOI: 10.1136/hrt.39.5.540

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  22 in total

1.  QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

Authors:  A SELZER; H W WRAY
Journal:  Circulation       Date:  1964-07       Impact factor: 29.690

2.  FURTHER EXPERIENCE OF ELECTRICAL CONVERSION OF ATRIAL FIBRILLATION TO SINUS RHYTHM: ANALYSIS OF 100 PATIENTS.

Authors:  S ORAM; J P DAVIES
Journal:  Lancet       Date:  1964-06-13       Impact factor: 79.321

3.  [Quinidine treatment of 390 cases of atrial fibrillation].

Authors:  J Acar; J Lenegre; P Maurice; R Rulliere
Journal:  Arch Mal Coeur Vaiss       Date:  1956-07

4.  Long-term evaluation of lidoflazine in angina pectoris based on exercise tolerance.

Authors:  J Piessens; H De Geest
Journal:  Cardiology       Date:  1972       Impact factor: 1.869

5.  Cardioversion and treatment of chronic atrial dysrhythmias with guinidine or lidoflazine: a comparative study.

Authors:  C De Vil; K Bruyneel
Journal:  Acta Cardiol       Date:  1974       Impact factor: 1.718

6.  Lidoflazine: a new drug in the treatment of angina pectoris.

Authors:  V Bernstein; D I Peretz
Journal:  Curr Ther Res Clin Exp       Date:  1972-08

7.  Lidoflazine and angina pectoris: a placebo-controlled double-blind study.

Authors:  C Aravanis; E Counelis; D Ieremias
Journal:  Curr Ther Res Clin Exp       Date:  1973-06

8.  Influence of lidoflazine on cardiac transmembrane potentials and experimental arrhythmias.

Authors:  E Carmeliet; R Xhonneux
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1971

9.  Antifibrillatory effects of lidoflazine. A clinical study.

Authors:  M Schlepper; R Derro
Journal:  Arzneimittelforschung       Date:  1972-05

10.  Evaluation of lidoflazine as an anti-anginal drug.

Authors:  J K Vohra; J G Sloman
Journal:  Cardiology       Date:  1973       Impact factor: 1.869

View more
  5 in total

Review 1.  Assessment of the risk-benefit ratio for antiarrhythmic drug use.

Authors:  R W Campbell
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation.

Authors:  G Nichol; F McAlister; B Pham; A Laupacis; B Shea; M Green; A Tang; G Wells
Journal:  Heart       Date:  2002-06       Impact factor: 5.994

Review 3.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

5.  Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Authors:  Lucie Valembois; Etienne Audureau; Andrea Takeda; Witold Jarzebowski; Joël Belmin; Carmelo Lafuente-Lafuente
Journal:  Cochrane Database Syst Rev       Date:  2019-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.